The actions of ROCK inhibitors that exceed the effect of the ROCK1nc mutation on kinase activity, combined with the widespread targeting of apoptotic and non-apoptotic cells, likely accounts for the differences observed for neutrophil and CD8+ T cells in HCC tumours between the genetic ROCK1nc modification and pharmacological ROCK inhibition. This evidence concerns the gene CD8A and hepatocellular carcinoma.